Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)’. The study aims to assess whether maridebart cafraglutide can reduce heart failure events and improve symptoms in patients with heart failure and obesity.
The intervention being tested is maridebart cafraglutide, administered subcutaneously, intended to reduce heart failure events and improve cardiovascular outcomes. A placebo is used as a comparator.
This is a randomized, double-blind, placebo-controlled study with a parallel intervention model. Both participants and investigators are masked to the treatment allocation. The primary purpose is treatment-focused.
The study began on June 25, 2025, with the primary completion and estimated completion dates yet to be determined. The last update was submitted on July 24, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
Amgen’s ongoing study could influence its stock performance positively if the results demonstrate significant efficacy and safety of maridebart cafraglutide. Investors should watch for updates as the study progresses, especially in the context of heart failure treatment advancements.
The study is currently recruiting, with further details available on the ClinicalTrials portal.